SEC Comment Letter 0000000000-25-000734 to Biodexa Pharmaceuticals Plc (BDRX)
Biodexa Pharmaceuticals Plc
Date: Jan. 23, 2025 · CIK: 0001643918 · Accession: 0000000000-25-000734
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284350
Letter
January 23, 2025 Stephen Stamp Chief Executive Officer Biodexa Pharmaceuticals PLC 1 Caspian Point Caspian Way Cardiff, CF10 4DQ, United Kingdom Re:Biodexa Pharmaceuticals PLC Registration Statement on Form F-1 Filed January 17, 2025 File No. 333-284350 Dear Stephen Stamp: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jason S. McCaffrey
Show Raw Text
January 23, 2025
Stephen Stamp
Chief Executive Officer
Biodexa Pharmaceuticals PLC
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ, United Kingdom
Re:Biodexa Pharmaceuticals PLC
Registration Statement on Form F-1
Filed January 17, 2025
File No. 333-284350
Dear Stephen Stamp:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jason S. McCaffrey